PIPELINE
DRUG CANDIDATE | TARGET | AREA | PLATFORM | DISCOVERY | PRECLINICAL | Phase I | Phase II |
RS-0139 | Integrin | Oncology | SagittaTM Bir | ||||
RS-0337 | HER2 | Oncology | SagittaTM Dui |
|
|||
RS-0461 | Integrin | Oncology | SagittaTM Dui |
|
|||
RS-0625 | Integrin | Oncology | SagittaTM Bir |
|
|||
RS-0735 | Undisclosed | Oncology | SagittaTM Bir |
|
DRUG | TARGET | AREA | PLATFORM | PHASE |
---|
RS-0139 | Integrin | Oncology | SagittaTM Bir | PhI Dose Escalation |
RS-0337 | HER2 | Oncology | SagittaTM Dui | Preclinical |
RS-0461 | Integrin | Oncology | SagittaTM Dui | Preclinical |
RS-0625 | Integrin | Oncology | SagittaTM Bir | Preclinical |
RS-0735 | Undisclosed | Oncology | SagittaTM Bir | Preclinical |